LncRNA SSTR5-AS1 promotes esophageal carcinoma through regulating ITGB6/JAK1/STAT3 signaling.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY Epigenomics Pub Date : 2024-01-01 Epub Date: 2024-09-05 DOI:10.1080/17501911.2024.2388018

Zhaohui Tang, Yongjun Jiang, Yuyu Zong, Sijuan Ding, Chen Wu, Zhangwen Tang, Lin Liao, Shaohui Jiang, Ruoting Tang, Fang Li, Pengfei Luo

{"title":"LncRNA SSTR5-AS1 promotes esophageal carcinoma through regulating ITGB6/JAK1/STAT3 signaling.","authors":"Zhaohui Tang, Yongjun Jiang, Yuyu Zong, Sijuan Ding, Chen Wu, Zhangwen Tang, Lin Liao, Shaohui Jiang, Ruoting Tang, Fang Li, Pengfei Luo","doi":"10.1080/17501911.2024.2388018","DOIUrl":null,"url":null,"abstract":"Aim: To investigate function of somatostatin receptor 5 antisense RNA 1 (SSTR5-AS1) in esophageal carcinoma (ESCA).Materials & methods: The cellular function was assessed using EdU staining and Transwell assay. The localization of SSTR5-AS1 was measured using fluorescence in situ hybridization staining.Results: SSTR5-AS1 shRNA repressed invasion and migration and induced apoptosis in ESCA cells. SSTR5-AS1 was distributed in cytoplasm, and it regulated its subunit integrin beta 6 (ITGB6) via eukaryotic translation initiation factor 4A3 (EIF4A3). SSTR5-AS1 shRNA inactivated ITGB6 and JAK1/STAT3 signaling. SSTR5-AS1 silencing attenuated the malignant behavior of ESCA cells through the ITGB6-mediated JAK1/STAT3 axis.Conclusion: SSTR5-AS1 promotes tumorigenesis of ESCA by interacting with EIF4A3 to regulate ITGB6/JAK1/STAT3 axis, which serves a basis for discovering strategies against ESCA.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"1133-1148"},"PeriodicalIF":2.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457597/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17501911.2024.2388018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/5 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To investigate function of somatostatin receptor 5 antisense RNA 1 (SSTR5-AS1) in esophageal carcinoma (ESCA).Materials & methods: The cellular function was assessed using EdU staining and Transwell assay. The localization of SSTR5-AS1 was measured using fluorescence in situ hybridization staining.Results: SSTR5-AS1 shRNA repressed invasion and migration and induced apoptosis in ESCA cells. SSTR5-AS1 was distributed in cytoplasm, and it regulated its subunit integrin beta 6 (ITGB6) via eukaryotic translation initiation factor 4A3 (EIF4A3). SSTR5-AS1 shRNA inactivated ITGB6 and JAK1/STAT3 signaling. SSTR5-AS1 silencing attenuated the malignant behavior of ESCA cells through the ITGB6-mediated JAK1/STAT3 axis.Conclusion: SSTR5-AS1 promotes tumorigenesis of ESCA by interacting with EIF4A3 to regulate ITGB6/JAK1/STAT3 axis, which serves a basis for discovering strategies against ESCA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

LncRNA SSTR5-AS1 通过调控 ITGB6/JAK1/STAT3 信号促进食管癌的发生

目的：研究体生长抑素受体5反义RNA 1（SSTR5-AS1）在食管癌（ESCA）中的功能：采用EdU染色和Transwell试验评估细胞功能。荧光原位杂交染色法测定 SSTR5-AS1 的定位：结果：SSTR5-AS1 shRNA抑制了ESCA细胞的侵袭和迁移，并诱导了细胞凋亡。SSTR5-AS1分布于细胞质中，通过真核翻译起始因子4A3（EIF4A3）调控其亚基整合素β6（ITGB6）。SSTR5-AS1 shRNA能使ITGB6和JAK1/STAT3信号失活。通过ITGB6介导的JAK1/STAT3轴，沉默SSTR5-AS1可减轻ESCA细胞的恶性行为：结论：SSTR5-AS1通过与EIF4A3相互作用来调控ITGB6/JAK1/STAT3轴，从而促进ESCA的肿瘤发生。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.